PLRX
PLIANT THERAPEUTICS, INC.
$1.15
0.00%
$71.2M
No data for this timeframe.
Vol
Market Cap$71.2M
Cap SizeMicro Cap
Analyst ConsensusSell (9%)
Inst. Holders7 funds
Inst. Value$7.4M
Inst. Activity0 buys / 2 sells
Reddit Sentiment60° Warm
SEC Reports6
Recent Activity
May 11, 2026
SEC
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue bio
PRESS-RELEASE — Impact 6/10
May 11, 2026
SEC
Pliant Therapeutics reported Q1 2026 results with a net loss of $20.0M ($0.32/share), narrower than the $56.2M loss in Q
8-K — Impact 4/10
Apr 17, 2026
SEC
Pliant Therapeutics announced the retirement of three board members effective at the 2026 Annual Meeting and a broad sto
8-K — Impact 6/10
Apr 17, 2026
Insider
Cummings Keith Lamont sold 76,047 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 17, 2026
Insider
Cheung Lily sold 123,000 shares
Chief Human Resource Officer @ $0.00 ($0.00)
Apr 17, 2026
Insider
Cummings Keith Lamont sold 76,047 shares
Chief Financial Officer @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — NEAR_EXIT
548,962 shares ($669.7K)
Inst.
FMR LLC — TRIM
1,934 shares ($2.4K)
Price Targets
$2.67
+124.1% upside
Strong Buy
Current $1.19
Low $2.00
Median $3.00
High $3.00
3 analysts
$2.00
$3.00
Analyst Ratings
0Strong Buy
1Buy
6Hold
2Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Hold → Hold |
| Mar 12, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.35 ▲ +7.3% | $-0.37 — $-0.32 | 51% YoY | 5 |
| Next Q | $-0.37 ▲ +2.6% | $-0.42 — $-0.32 | 14% YoY | 5 |
| Current FY | $-1.42 ▲ +7.2% | $-1.56 — $-1.29 | 41% YoY | 5 |
| Next FY | $-0.95 ▲ +37.3% | $-1.53 — $0.49 | 33% YoY | 5 |
Latest Reports
BEARISH
PRESS-RELEASE
6/10
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue bio
May 11, 2026
NEUTRAL
8-K
4/10
Pliant Therapeutics reported Q1 2026 results with a net loss of $20.0M ($0.32/share), narrower than the $56.2M loss in Q
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $3.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $1.2M | DOUBLED |
| BANK OF AMERICA CORP | $868.4K | ADD |
| MORGAN STANLEY | $669.7K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 17, 2026 | Cummings Keith | D | $0.00 |
| Apr 17, 2026 | Cheung Lily | D | $0.00 |
| Apr 17, 2026 | Cummings Keith | A | $0.00 |
| Apr 17, 2026 | Cheung Lily | A | $0.00 |
| Apr 17, 2026 | Kuo Minnie | A | $0.00 |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $7.4M total value (6,080,075 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,818,241 | $3.4M | 46.4% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,045,818 | $1.3M | 17.2% | DOUBLED +406.0% |
| 3 | TWO SIGMA INVESTMENTS, LP | 953,293 | $1.2M | 15.7% | DOUBLED +181.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 711,777 | $868.4K | 11.7% | ADD +47.3% |
| 5 | MORGAN STANLEY | 548,962 | $669.7K | 9.0% | NEAR_EXIT -84.3% |
| 6 | FMR LLC | 1,934 | $2.4K | 0.0% | TRIM -61.1% |
| 7 | WELLS FARGO & COMPANY/MN | 50 | $61.00 | 0.0% | NEAR_EXIT -97.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 3,507,288 | 548,962 | -84.3% | $669.7K | 2025-Q4 |
| FMR LLC | TRIM | 4,974 | 1,934 | -61.1% | $2.4K | 2025-Q4 |
| UBS Group AG | TRIM | 2,646,556 | 1,322,017 | -50.0% | $2.0M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 199,948 | 1,011,802 | +406.0% | $1.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 278,158 | 783,255 | +181.6% | $1.2M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 480,530 | 708,056 | +47.3% | $1.0M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 2,329 | 50 | -97.9% | $74.00 | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 251,365 | 0 | -100.0% | $0.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 920,736 | 480,530 | -47.8% | $557.4K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 389,349 | 251,365 | -35.4% | $291.6K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 152,500 | 199,948 | +31.1% | $231.9K | 2025-Q2 |
| FMR LLC | TRIM | 22,210 | 6,507 | -70.7% | $7.5K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 35,451 | 2,329 | -93.4% | $2.7K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 782,004 | 3,051,514 | +290.2% | $4.1M | 2025-Q1 |
| UBS Group AG | DOUBLED | 628,281 | 2,645,546 | +321.1% | $3.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 97,078 | 275,287 | +183.6% | $371.6K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 27,800 | 152,500 | +448.6% | $205.9K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 494,489 | 45,165 | -90.9% | $61.0K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 85,880 | 35,451 | -58.7% | $47.9K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 3,876,598 | 22,210 | -99.4% | $30.0K | 2025-Q1 |
| UBS Group AG | DOUBLED | 230,308 | 628,281 | +172.8% | $8.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 112,954 | 494,489 | +337.8% | $6.5M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 101,200 | 27,800 | -72.5% | $366.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 456,663 | — | $5.1M | 2024-Q3 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 17, 2026 | Cummings Keith Lamont | Chief Financial Officer | D | 76,047 | $0.00 | $0.00 |
| Apr 17, 2026 | Cheung Lily | Chief Human Resource Officer | D | 123,000 | $0.00 | $0.00 |
| Apr 17, 2026 | Cummings Keith Lamont | Chief Financial Officer | A | 76,047 | $0.00 | $0.00 |
| Apr 17, 2026 | Cheung Lily | Chief Human Resource Officer | A | 123,000 | $0.00 | $0.00 |
| Apr 17, 2026 | Kuo Minnie | Chief Operating Officer | A | 150,000 | $0.00 | $0.00 |
| Apr 17, 2026 | Coulie Bernard | President and CEO | D | 146,841 | $0.00 | $0.00 |
| Apr 17, 2026 | Coulie Bernard | President and CEO | A | 146,841 | $0.00 | $0.00 |
| Apr 17, 2026 | Kuo Minnie | Chief Operating Officer | D | 150,000 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 3 neutral. Avg impact: 5.0/10.
BEARISH
PRESS-RELEASE
6/10
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was
May 11, 2026
NEUTRAL
8-K
4/10
Pliant Therapeutics reported Q1 2026 results with a net loss of $20.0M ($0.32/share), narrower than
May 11, 2026
MIXED
8-K
6/10
Pliant Therapeutics announced the retirement of three board members effective at the 2026 Annual Mee
Apr 17, 2026
NEUTRAL
EFFECT
4/10
Pliant Therapeutics' $300 million shelf registration, including a $50 million at-the-market (ATM) of
Apr 7, 2026
BULLISH
8-K
7/10
Pliant Therapeutics reported fourth quarter 2025 financial results and provided a corporate update,
Mar 11, 2026
NEUTRAL
8-K
3/10
Pliant Therapeutics extended the expiration date of its shareholder rights agreement from March 11,
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Sell (9% buy). Based on 11 analysts: 0 strong buy, 1 buy, 6 hold, 2 sell, 2 strong sell.
Analyst Price Targets
$2.67 mean target
+124.1% upside
Strong Buy (3.00)
$2.00 Low
$3.00 High
| Metric | Value |
|---|---|
| Current Price | $1.19 |
| Target Low | $2.00 |
| Target Mean | $2.67 |
| Target Median | $3.00 |
| Target High | $3.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.35 | $-0.37 | $-0.32 | 51.3% | +7.3% | 3↑ 0↓ | $0.0B | 0.0% | 5 |
| Next Q 2026-09-30 |
$-0.37 | $-0.42 | $-0.32 | 14.1% | +2.6% | 2↑ 0↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-1.42 | $-1.56 | $-1.29 | 40.8% | +7.2% | 4↑ 0↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-0.95 | $-1.53 | $0.49 | 33.1% | +37.3% | 5↑ 0↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.346 | |
| 7d ago | $-0.350 | +0.004 |
| 30d ago | $-0.373 | +0.027 |
| 60d ago | $-0.373 | +0.027 |
| 90d ago | $-0.453 | +0.108 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Hold | Hold |
| Mar 12, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% | |
| May 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% | |
| Apr 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% | |
| Mar 1, 2026 | 0 | 1 | 7 | 2 | 2 | 8% | |
| Feb 1, 2026 | 0 | 1 | 7 | 2 | 2 | 8% | |
| Jan 1, 2026 | 0 | 1 | 7 | 2 | 2 | 8% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Pliant Therapeutics - Institutional holdings
▲ 4
💬 2
⚡ 0.0
May 21, 2026
routine
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
<p align="center"><em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 </em><br><em>enrolling patients with ICI-refractory so
May 11, 2026
earnings
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
<p align="center"><em>First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095</em><br><br><em>Oral presentation at AAC
May 11, 2026
earnings_calendar
PLRX Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
other
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
<p>SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company fo
May 6, 2026
earnings_calendar
PLRX Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
other
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
<p align="left">SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the
Apr 18, 2026
routine
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
<p align="center"><em>Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased
Mar 11, 2026
earnings
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
<p align="center"><em>PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors</em></p>
Mar 3, 2026
earnings_calendar
PLRX Q4 2025 Earnings After Market Close — 2026-03-03
Mar 2, 2026
earnings_calendar
PLRX Q4 2025 Earnings After Market Close — 2026-03-02